glp-1 agonists and sglt2 inhibitors Diabetic Agents, From Metformin to GLP1 Receptor Agonists: JACC Focus Seminar Type 2 Diabetes: The Effects

Garg continued

10 or 15 mg once weekly) vs Reduce to tirzepatide 5 mg once weekly vs Placebo for 52 weeks (randomized 3:3:2 at week 60) Primary outcome: Percent change in bodyweight from baseline to week 112 Results: Primary outcome (percent change in bodyweight at week 112): Tirzepatide MTD -21.9%, Tirzepatide 5 mg -16.6%, Placebo -9.9% (estimated treatment difference vs placebo -12.0% for MTD and -6.6% for 5 mg

FIGURE 2 2.1.1 Calcium channel modulation Recent research has shown that exendin-4, a GLP-1RA, suppresses L-type voltage-gated calcium channels (L-VGCC) activity through a cascade involving cAMP/PKA, ryanodine receptors, and calmodulin (CaM)

That does not make it a GLP-1 medication

Individuals taking Wegovy, particularly older adults, may be at a higher risk of developing NAION and should seek medical attention immediately for blurred vision, blindness, or other sight concerns

Monitoring and Follow-Up Care Regular medical supervision is essential when using GLP-1 medications, regardless of where you purchase them